Pharmacokinetics, Bioavailability and Safety of PENNSAID® Gel

Completed · Phase 1

Conditions studied: Pain

In brief

It is anticipated that PENNSAID Gel will minimize systemic exposure versus oral diclofenac administered twice a day (BID). In addition, PENNSAID Gel should result in greater subject convenience and compliance with a comparable bioavailability, safety and tolerability profile to that of the approved PENNSAID solution administered four times a day (QID).

Key facts

Study ID

NCT01202799

Run by

Mallinckrodt

People needed

30

Starts

2010-09-01

Expected to finish

2010-11-01

Last updated by the study team

2014-09-23

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The eligibility of subjects to enter the study is based on meeting the inclusion criteria listed below:
• Signed and dated IRB approved consent before any protocol procedures are performed.
• Males or non-pregnant, non-lactating females, minimum 18 years of age and maximum of 55 years of age.
• Female subjects must be negative on a serum pregnancy test, be postmenopausal for at least 1 year, surgically sterile, or using an acceptable form of contraception for 30 days prior to dosing and for the duration of study participation.
• Subjects with a body mass index (BMI) ≥19 and ≤29 kg/m².
• The findings from the ECG interpretation must be within the normal range.
• Subjects whose health status is assessed by the investigator as "normal healthy" by required screening and check-in assessments.
• Subjects must be able to provide written consent and agree to comply with study requirements.

You may not qualify if…

• Subjects will be ineligible for the study if they meet any of the following criteria:
• Known hypersensitivity to diclofenac, aspirin [acetylsalicylic acid (ASA)] or any other NSAID, dimethyl sulfoxide (DMSO) or ethanol. This includes subjects exhibiting aspirin or other NSAID-induced symptoms, including bronchospasm, rhinitis, and urticaria or other NSAID-induced allergic symptoms.
• Pregnant or lactating women. Women of reproductive potential (and women <12 months after menopause) may not participate unless they have agreed to use an effective contraceptive method while on study.
• Evidence of any serious active infections, severe uncontrolled cardiac, renal, hepatic, pulmonary or other systemic disease, significant medical or psychiatric illness, known seropositivity to HIV, known unexplained vision changes, history of unexplained syncope, lightheadedness, high blood pressure, chronic hepatic conditions like hepatic porphyria or clinically significant laboratory findings that would, in the investigators judgment, make the subject inappropriate for the study.
• Documented (upper GI series or endoscopy) gastroduodenal ulcer or any GI bleeding (except hemorrhoidal) within the last 6 months prior to screening.
• Abnormal hepatic and renal functions; hematologic changes:
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)≥2.5 X ULN
• Gamma-glutamyl transpeptidase (GGT) ≥3X ULN
• Total bilirubin ≥1.5X ULN
• Serum creatinine ≥1.5X ULN
• Hemoglobin ≤LLN.
• Major surgery or previous damage to the study knee(s) at any time (eg. total knee replacement, damage/reconstruction of the anterior or posterior cruciate ligaments), or minor knee surgery (eg, cartilage repair, collateral ligament repair, arthroscopic debridement) to the study knee(s) within 1 year prior to screening.
• Administration of a sedative hypnotic medication for insomnia within 14 days prior to screening.
• Administration of anti-depressants, within 60 days prior to screening.
• Administration of another investigational drug within the previous 30 days prior to screening.
• Skin disorder that affects palms of the hands or the application site of the knee(s).
• History of chronic headaches.
• Documented history of alcohol or drug abuse within 1 year prior to the screening visit
• Subjects who have smoked or used nicotine-containing products within 6 months prior to Period 1 dosing.
• Subjects treated with systemic or local diclofenac within one month of study Day 1.
• Using artificial exposure, tanning beds, or self-tanning cream on knee area within 90 days of study start.
• Donation or significant loss of blood (480 mL or more) within 30 days of dosing.
• Previous participation in this study or participation in another clinical trial within 30 days prior screening.
• Noncompliance with the study protocol.

Where it is running

• Comprehensive Phase One — Miramar, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.